Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Antonio Ceriello; Helena W Rodbard; Tadej Battelino; Frank Brosius; Francesco Cosentino; Jennifer Green; Linong Ji; Monika Kellerer; Susan Koob; Mikhail Kosiborod; Nebojsa Lalic; Nikolaus Marx; T Prashant Nedungadi; Christopher G Parkin; Lars Rydén; Wayne Huey-Herng Sheu; Eberhard Standl; Per Olav Vandvik; Oliver Schnell; Taskforce of the Guideline Workshop

doi:10.1186/s12933-023-01993-3

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Cardiovasc Diabetol. 2023 Oct 13;22(1):277. doi: 10.1186/s12933-023-01993-3.

Authors

Antonio Ceriello¹, Helena W Rodbard², Tadej Battelino³, Frank Brosius⁴, Francesco Cosentino⁵, Jennifer Green⁶, Linong Ji⁷, Monika Kellerer⁸, Susan Koob⁹, Mikhail Kosiborod^{10

11}, Nebojsa Lalic¹², Nikolaus Marx¹³, T Prashant Nedungadi¹⁴, Christopher G Parkin¹⁵, Lars Rydén¹⁶, Wayne Huey-Herng Sheu¹⁷, Eberhard Standl¹⁸, Per Olav Vandvik¹⁹, Oliver Schnell²⁰; Taskforce of the Guideline Workshop

Affiliations

¹ IRCCS MultiMedica, Via Milanese 300, 20099, Sesto San Giovanni, MI, Italy.
² Endocrine and Metabolic Consultants, 3200 Tower Oaks Blvd., Suite 250, Rockville, MD, 20852, USA.
³ University Medical Center Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
⁴ University of Arizona College of Medicine, 1501 N. Campbell Ave, Tucson, AZ, 85724-5022, USA.
⁵ Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Solna, Stockholm, Sweden.
⁶ Duke University Medical Center, Duke Clinical Research Institute, 200 Morris St, DUMC Box 3850, Durham, NC, 27715, USA.
⁷ Peking University People's Hospital, 11 Xizhimen S St, Xicheng District, Beijing, China.
⁸ Marienhospital Stuttgart, Böheimstraße 37, 70199, Stuttgart, Germany.
⁹ PCNA National Office, 613 Williamson Street, Suite 200, Madison, WI, 53703, USA.
¹⁰ Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, 4401 Wornall Rd, Kansas City, MO, 64111, USA.
¹¹ The George Institute for Global Health and University of New South Wales, Sydney, Australia.
¹² University Clinical Center of Serbia, University of Belgrade, Pasterova 2, 11000, Belgrade, Serbia.
¹³ Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
¹⁴ American Heart Association, 7272 Greenville Avenue, Dallas, TX, 75082, USA.
¹⁵ CGParkin Communications, Inc., 2675 Windmill Pkwy, Suite 2721, Henderson, NV, 89074, USA.
¹⁶ Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.
¹⁷ Institute of Molecular and Genomic Medicine, National Research Health Institutes, Zhunan, Miaoli, 350, Taiwan.
¹⁸ Forschergruppe Diabetes E. V, Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany.
¹⁹ Institute of Health and Society, University of Oslo, Oslo, Norway.
²⁰ Forschergruppe Diabetes E. V, Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany. [email protected].

Abstract

In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.

Keywords: (GIP RA); Finerenone; Glucagon-like peptide-1 receptor agonist (GLP-1 RA); Glucose-dependent insulinotropic polypeptide; Network meta-analysis; Randomized controlled trial; Sodium glucose cotransporter 2 inhibitor; Tirzepatide.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / adverse effects
Kidney
Network Meta-Analysis
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents